Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Naive B Cell Output in HIV-Infected and HIV-Uninfected Children.
Payne H, Chain G, Adams S, Hunter P, Luckhurst N, Gilmour K, Lewis J, Babiker A, Cotton M, Violari A, Gibb D, Callard R, Klein N. Payne H, et al. Among authors: babiker a. AIDS Res Hum Retroviruses. 2019 Jan;35(1):33-39. doi: 10.1089/AID.2018.0170. Epub 2018 Dec 26. AIDS Res Hum Retroviruses. 2019. PMID: 30298747 Free PMC article.
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study. Phillips AN, et al. Among authors: babiker a. AIDS. 2007 Aug 20;21(13):1717-21. doi: 10.1097/QAD.0b013e32827038bf. AIDS. 2007. PMID: 17690569
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
PENPACT-1 (PENTA 9/PACTG 390) Study Team; Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. PENPACT-1 (PENTA 9/PACTG 390) Study Team, et al. Among authors: babiker a. Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31. Lancet Infect Dis. 2011. PMID: 21288774 Free PMC article. Clinical Trial.
Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.
Lange CM, Hué S, Violari A, Cotton M, Gibb D, Babiker A, Otwombe K, Panchia R, Dobbels E, Jean-Philippe P, McIntyre JA, Pillay D, Gupta RK. Lange CM, et al. Among authors: babiker a. J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):138-44. doi: 10.1097/QAI.0000000000000568. J Acquir Immune Defic Syndr. 2015. PMID: 25923117 Free PMC article. Clinical Trial.
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.
Payne H, Mkhize N, Otwombe K, Lewis J, Panchia R, Callard R, Morris L, Babiker A, Violari A, Cotton MF, Klein NJ, Gibb DM. Payne H, et al. Among authors: babiker a. Lancet Infect Dis. 2015 Jul;15(7):803-9. doi: 10.1016/S1473-3099(15)00087-0. Epub 2015 Jun 1. Lancet Infect Dis. 2015. PMID: 26043884 Free PMC article. Clinical Trial.
HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team. Harrison L, et al. Among authors: babiker a. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671. J Acquir Immune Defic Syndr. 2015. PMID: 26322666 Free PMC article. Clinical Trial.
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K, Inshaw J, Ford D, Bernays S, Scott K, Kenny J, Klein N, Turkova A, Harper L, Nastouli E, Paparini S, Choudhury R, Rhodes T, Babiker A, Gibb D. Butler K, et al. Among authors: babiker a. Health Technol Assess. 2016 Jun;20(49):1-108. doi: 10.3310/hta20490. Health Technol Assess. 2016. PMID: 27377073 Free PMC article. Clinical Trial.
The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group. Lodi S, et al. Among authors: babiker a. AIDS. 2016 Nov 13;30(17):2659-2663. doi: 10.1097/QAD.0000000000001243. AIDS. 2016. PMID: 27782964 Free PMC article. Clinical Trial.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpantmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group. Turkova A, et al. Among authors: babiker a. PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239. eCollection 2018. PLoS One. 2018. PMID: 29684092 Free PMC article. Clinical Trial.
625 results